{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T07:11:07Z","timestamp":1772349067593,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T00:00:00Z","timestamp":1418256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s12072-014-9593-x","type":"journal-article","created":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T04:52:21Z","timestamp":1418187141000},"page":"43-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Reimbursement policies in the Asia-Pacific for chronic hepatitis B"],"prefix":"10.1007","volume":"9","author":[{"given":"Seng Gee","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak N.","family":"Amarapurkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Lik-Yuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell H.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Gane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang-Hyub","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasim","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurentius A.","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Rinaldi A.","family":"Lesmana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosmawati","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pham Hoang","family":"Phiet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiv K.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose D.","family":"Sollarno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamun-Al","family":"Mahtab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keat Hong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,11]]},"reference":[{"issue":"Suppl 1","key":"9593_CR1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1386-6532(05)00384-7","volume":"34","author":"D Lavanchy","year":"2005","unstructured":"Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2005;34(Suppl 1):S1\u2013S3","journal-title":"J Clin Virol"},{"key":"9593_CR2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"Lozano","year":"2012","unstructured":"Lozano, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. The Lancet. 2012;380:2095\u20132128","journal-title":"The Lancet"},{"key":"9593_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1478-3231.2006.01370.x","volume":"26","author":"LA Lesmana","year":"2006","unstructured":"Lesmana LA, Mahachai V, Phiet PH, Suh DJ, Yao GB. Hepatitis B: overview of the burden of disease in the Asia-Pacific region. Liver Int. 2006;26:3\u201310","journal-title":"Liver Int"},{"key":"9593_CR4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12072-008-9049-2","volume":"2","author":"YY Dan","year":"2008","unstructured":"Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepato Int. 2008;2:284\u2013295","journal-title":"Hepato Int"},{"issue":"47","key":"9593_CR5","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","volume":"27","author":"X Liang","year":"2009","unstructured":"Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China: declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550\u20136557","journal-title":"Vaccine"},{"issue":"2","key":"9593_CR6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cll.2012.03.003","volume":"32","author":"P Abraham","year":"2012","unstructured":"Abraham P. Viral hepatitis in India. Clin Lab Med. 2012;32(2):159\u2013174","journal-title":"Clin Lab Med"},{"issue":"8","key":"9593_CR7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","volume":"12","author":"MF Yuen","year":"2007","unstructured":"Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther. 2007;12(8):1295\u20131303","journal-title":"Antivir Ther"},{"issue":"15","key":"9593_CR8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"Y-F Liaw","year":"2004","unstructured":"Liaw Y-F, Sung JJY, Chow WC, Farrell G, Lee C-Z, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521\u20131531","journal-title":"N Engl J Med"},{"key":"9593_CR9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T, et al. Asia-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531\u2013561","journal-title":"Hepatol Int"},{"key":"9593_CR10","unstructured":"Pharmaceutical Benefits Scheme. http:\/\/pbs.gov.au\/pbs\/home . Accessed 1 September 2014"},{"key":"9593_CR11","unstructured":"The Hepatitis Foundation of New Zealand. http:\/\/www.hepatitisfoundation.org.nz\/ . Accessed 1 September 2014"},{"key":"9593_CR12","unstructured":"Pharmaceutical Management Agency. http:\/\/www.pharmac.health.nz\/ . Accessed 1 September 2014"},{"key":"9593_CR13","unstructured":"National Health Insurance Administration, Ministry of Health and Welfare. http:\/\/www.nhi.gov.tw\/search\/search_English.aspx?qwords=hepatitis . Accessed 1 September 2014"},{"key":"9593_CR14","unstructured":"PhilHealth. http:\/\/www.philhealth.gov.ph . Accessed 1 September 2014"},{"key":"9593_CR15","unstructured":"Thai Association for the Study of the Liver. http:\/\/www.moh.gov.kh\/?page_id=235&lang=en . Accessed 1 September 2014"},{"key":"9593_CR16","unstructured":"Ministry of Health. http:\/\/www.moh.gov.kh\/?page_id=235&lang=en . Accessed 1 September 2014"},{"issue":"1","key":"9593_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hepr.12108","volume":"44","author":"A Tanaka","year":"2014","unstructured":"Tanaka A. JSG Guidelines for the management of hepatitis B virus infection. Hepatol Res. 2014;44(1):1\u201358","journal-title":"Hepatol Res"},{"key":"9593_CR18","unstructured":"Japan Ministry of Health, Labour and Welfare. http:\/\/www.mhlw.go.jp\/stf\/houdou\/0000031326.html . Accessed 1 September 2014"},{"key":"9593_CR19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3350\/cmh.2012.18.2.109","volume":"18","author":"BC Yoo","year":"2012","unstructured":"Yoo BC. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109\u2013162","journal-title":"Clin Mol Hepatol"},{"key":"9593_CR20","unstructured":"Ministry of Health and Welfare. http:\/\/english.mw.go.kr\/ . Accessed 1 September 2014"},{"key":"9593_CR21","unstructured":"Ministry of Human Resources and Social Security of the People\u2019s Republic of China. http:\/\/www.mohrss.gov.cn\/gkml\/xxgk\/201407\/t20140717_136141.htm . Accessed 2 September 2014"},{"issue":"10","key":"9593_CR22","doi-asserted-by":"crossref","first-page":"e78662","DOI":"10.1371\/journal.pone.0078662","volume":"8","author":"P Herck Van","year":"2013","unstructured":"Van Herck P, Annemans L, Sermeus W, Ramaekers D. Evidence-based health care policy in reimbursement decisions: lessons from a series of six equivocal case-studies. PLoS ONE. 2013;8(10):e78662","journal-title":"PLoS ONE"},{"issue":"2","key":"9593_CR23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s12072-012-9399-7","volume":"7","author":"KH Lee","year":"2013","unstructured":"Lee KH, Aung MO, Lim SG. Are physicians following guidelines? A survey of hepatitis B management strategies. Hepatol Int. 2013;7(2):451\u2013459","journal-title":"Hepatol Int"},{"issue":"3","key":"9593_CR24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12072-009-9139-9","volume":"3","author":"S Chainuvati","year":"2009","unstructured":"Chainuvati S, Cheng J, Hou JL, et al. Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in mainland China, South Korea, Taiwan, and Thailand. Hepatol Int. 2009;3(3):453\u2013460","journal-title":"Hepatol Int"},{"issue":"5","key":"9593_CR25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3851\/IMP2482","volume":"18","author":"SG Lim","year":"2013","unstructured":"Lim SG, Aung MO, Chung SW, Soon CS, Mak BH, Lee KH. Patient preferences for hepatitis B therapy. Antivir Ther. 2013;18(5):663\u2013670","journal-title":"Antivir Ther"},{"issue":"3","key":"9593_CR26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3851\/IMP2719","volume":"19","author":"V Arama","year":"2014","unstructured":"Arama V, Leblebicioglu H, Simon K, et al. Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. Antivir Ther. 2014;19(3):245\u2013257","journal-title":"Antivir Ther"},{"key":"9593_CR27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0272989X0002000310","volume":"20","author":"RA Hirth","year":"2000","unstructured":"Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality adjusted life year: in search of a standard. Med Decis Making. 2000;20:332\u2013342","journal-title":"Med Decis Making"},{"issue":"7530","key":"9593_CR28","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/bmj.38658.675243.94","volume":"331","author":"DB Evans","year":"2005","unstructured":"Evans DB, Lim SS, Adam T, Edejer T-T. Evaluation of current strategies and future priorities for improving health in developing countries. BMJ. 2005;331(7530):1457\u20131461","journal-title":"BMJ"},{"issue":"6","key":"9593_CR29","first-page":"913","volume":"148","author":"A Gafni","year":"1993","unstructured":"Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J. 1993;148(6):913\u2013917","journal-title":"Can Med Assoc J"},{"key":"9593_CR30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hec.639","volume":"10","author":"PP Sendi","year":"2001","unstructured":"Sendi PP, Briggs AH. Affordability and cost effectiveness: decision-making on the cost effectiveness plane. Health Econ. 2001;10:675\u2013680","journal-title":"Health Econ"},{"issue":"3","key":"9593_CR31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12072-008-9049-2","volume":"2","author":"YY Dan","year":"2008","unstructured":"Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int. 2008;2(3):284\u2013295","journal-title":"Hepatol Int"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-014-9593-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-014-9593-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-014-9593-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T04:09:46Z","timestamp":1650773386000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-014-9593-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,11]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["9593"],"URL":"https:\/\/doi.org\/10.1007\/s12072-014-9593-x","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,11]]}}}